GlucoTrack amends 8-K to add accountant review report for Lokahi interim financials

GlucoTrack filed an amended current report to add an independent accountant’s review report and unaudited condensed financial statements for Lokahi Therapeutics for the six months ended June 30, 2026.

The filing includes a going-concern emphasis, citing recurring operating losses and negative operating cash flow.

Lokahi reported a net loss of $8.1 million. Cash used in operations was $3.62 million, while cash and cash equivalents were $53,186.

The balance sheet showed total assets of $2.5 million, total liabilities of $9.24 million and shareholders’ deficit of $6.74 million.